Miriplatin hydrate

Used in lipiodolization for hepatocellular carcinoma treatment CAS# 250159-48-9

Miriplatin hydrate

Catalog No. BCC1751----Order now to get a substantial discount!

Product Name & Size Price Stock
Miriplatin hydrate: 5mg $207 In Stock
Miriplatin hydrate: 10mg Please Inquire In Stock
Miriplatin hydrate: 20mg Please Inquire Please Inquire
Miriplatin hydrate: 50mg Please Inquire Please Inquire
Miriplatin hydrate: 100mg Please Inquire Please Inquire
Miriplatin hydrate: 200mg Please Inquire Please Inquire
Miriplatin hydrate: 500mg Please Inquire Please Inquire
Miriplatin hydrate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Miriplatin hydrate

Number of papers citing our products

Chemical structure

Miriplatin hydrate

3D structure

Chemical Properties of Miriplatin hydrate

Cas No. 250159-48-9 SDF Download SDF
PubChem ID 23725065 Appearance Powder
Formula C34H70N2O5Pt M.Wt 782.01
Type of Compound N/A Storage Desiccate at -20°C
Solubility 25℃: DMSO
Chemical Name (1R,2R)-cyclohexane-1,2-diamine;platinum(2+);tetradecanoate;hydrate
SMILES CCCCCCCCCCCCCC(=O)[O-].CCCCCCCCCCCCCC(=O)[O-].C1CCC(C(C1)N)N.O.[Pt+2]
Standard InChIKey LWDBMUAJGMXQAY-GSEQGPDBSA-L
Standard InChI InChI=1S/2C14H28O2.C6H14N2.H2O.Pt/c2*1-2-3-4-5-6-7-8-9-10-11-12-13-14(15)16;7-5-3-1-2-4-6(5)8;;/h2*2-13H2,1H3,(H,15,16);5-6H,1-4,7-8H2;1H2;/q;;;;+2/p-2/t;;5-,6-;;/m..1../s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Miriplatin hydrate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Miriplatin hydrate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Miriplatin hydrate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.2788 mL 6.3938 mL 12.7876 mL 25.5751 mL 31.9689 mL
5 mM 0.2558 mL 1.2788 mL 2.5575 mL 5.115 mL 6.3938 mL
10 mM 0.1279 mL 0.6394 mL 1.2788 mL 2.5575 mL 3.1969 mL
50 mM 0.0256 mL 0.1279 mL 0.2558 mL 0.5115 mL 0.6394 mL
100 mM 0.0128 mL 0.0639 mL 0.1279 mL 0.2558 mL 0.3197 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Miriplatin hydrate

Description: IC50 Value: 22.3 microg/ml (7-day exposure, in rat ascites hepatoma AH-109A cells) [2] Miriplatin was approved for lipiodolization for the treatment of hepatocellular carcinoma in 2009. It is a lipophilic platinum complex containing myristates as leaving groups, and can be easily suspended in ethyl esters of iodized fatty acids obtained from poppy seed oil. in vitro: In monolayer or suspension cell cultures, SM-11355 did not inhibit the cell growth, whereas SM-11355/Lipiodol had dose-dependent growth inhibitory activities, as did CDDP suspended in Lipiodol (CDDP/Lipiodol) [1]. SM-11355 suspended in Lipiodol (SM-11355/Lipiodol) and CDDP suspended in Lipiodol (CDDP/Lipiodol) showed cytotoxic activity against rat ascites hepatoma AH-109A cells in a dose-dependent manner. Their IC50 values following 7-day exposure were 22.3 and 0.40 microg/ml, respectively. Following the subsequent 7-day exposure, from day 7 to day 14 after preparation of the suspension, SM-11355/Lipiodol showed an almost equivalent activity, but CDDP/Lipiodol did not show any activity at all [2]. in vivo: Tumor growth was suppressed in the group that received SM-11355 suspended in Lipiodol (SM-11355/Lipiodol). Mean tumor growth rates in the groups administered 20 microl of Lipiodol containing 0, 0.02, 0.04, 0.1, 0.2, or 0.4 mg of SM-11355 were 244, 86, 110, 81, 51, and 40%, respectively, 1 week after treatment [3]. Clinical trial: Launched drug.

Featured Products
New Products
 

References on Miriplatin hydrate

Comparison of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinoma.[Pubmed:23046493]

Hepatol Res. 2013 May;43(5):475-80.

AIM: The aim of this retrospective study was to compare the local control effects of transcatheter arterial chemoembolization (TACE) using epirubicin (EPIR) and that using miriplatin (MPT) for hepatocellular carcinoma (HCC). METHODS: Between January 2010 and July 2011, 218 HCC cases were treated with TACE, including 69 cases using EPIR or MPT as initial treatment. All 69 patients were treated with iodized oil and gelatin sponge particles. The local control rate (modified Response Evaluation Criteria in Solid Tumors [RECIST] ver. 1.0), time to treatment failure (Kaplan-Meier and log-rank test) and adverse events were evaluated. RESULTS: Forty-two cases were treated using EPIR, and 27 cases were treated using MPT. All 69 patients had no previous treatment with TACE or hepatic arterial infusion. No serious adverse events were observed in either group. The response rates, including complete response (CR) and partial response (PR), of the EPIR group and the MPT group were 85.7% and 81.5%, respectively, with a time to treatment failure of 5.1 and 7.5 months, respectively. Excluding whole liver TACE cases, time to treatment failure was 5.4 months for the EPIR group and 10.1 months for the MPT group. CONCLUSION: In TACE naive cases, there was no significant difference in local control between EPIR and MPT.

[Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355(miriplatin hydrate)--safety and efficacy in combination with embolizing agents].[Pubmed:20154484]

Gan To Kagaku Ryoho. 2010 Feb;37(2):271-5.

SM-11355 is a cisplatin derivative with high affinity for iodized ethyl esters of fatty acids of poppyseed oil. Clinical trials have shown that SM-11355 is effective for treatment of hepatocellular carcinoma. Transcatheter arterial chemoembolization is commonly used in combination with embolizing agents, but concomitant use of SM-11355 and embolizing agents has not been evaluated in previous trials. In this study, the safety and efficacy of SM-11355 in combination with embolizing agents were investigated in 10 patients with hepatocellular carcinoma. An anti-tumor effect of TE4 was achieved in 4 of 9 patients and no serious adverse events were observed, indicating that this therapy can be used safely for hepatocellular carcinoma.

Description

Miriplatin hydrate (SM-11355 hydrate) is a chemotherapy agent which belongs to the class of alkylating agents.

Keywords:

Miriplatin hydrate,250159-48-9,Natural Products,Lipophilic platinum complex, buy Miriplatin hydrate , Miriplatin hydrate supplier , purchase Miriplatin hydrate , Miriplatin hydrate cost , Miriplatin hydrate manufacturer , order Miriplatin hydrate , high purity Miriplatin hydrate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: